康方生物(09926.HK)新型肿瘤免疫治疗药物启动多项临床研究
康方生物(09926.HK)公布,公司自主研发的新型肿瘤免疫治疗药物PD-1/VEGF双特异性抗体(研发代号:AK112),在中国、澳大利亚等国家开展了剂量爬坡和扩展的I期临床研究後,再分别开展多项单药或联合用药的临床研究。
这是继全球首创的Cadonilimab(PD-1/CTLA-4双特异性抗体)在中国和美国同时推进注册性II期临床试验後,公司又一个率先进入後期临床阶段的全球首创双特异性抗体药物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.